Startseite The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases

  • Li Li , Xing Gu , Meng Fang , Jun Ji , Changhong Yi und Chunfang Gao EMAIL logo
Veröffentlicht/Copyright: 2. Juni 2015
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 54 Heft 4

Abstract

Background: Some changes of glycoproteins have been identified in the serum of patients with different liver diseases, which provided potential glycan biomarkers for diagnosis, prognosis and monitoring of disease progression.

Methods: We established a lectin-antibody sandwich ELISA method to detect fucosylated fetuin A (fuc-fetuin A) level in serum, in which biotinylated Aleuria aurantia lectin (AAL) was used for specific recognition. Then serum fuc-fetuin A level was detected in 108 healthy controls and 548 hepatitis B virus (HBV)-infected patients, including 232 hepatocellular carcinoma (HCC) patients, 114 liver cirrhosis (LC) patients, 86 liver fibrosis (LF) patients, and 116 asymptomatic HBV carriers, to assess its diagnostic and prognostic value in HBV-related liver diseases.

Results: Serum fetuin A level decreased in LC patients as compared to HCC patients or healthy controls, while it decreased further according to the increasing Child-Pugh grades. The fuc-fetuin A level was in a decreasing order in LC, HCC, LF, HBV-carriers and healthy controls. For distinguishing LC and HCC patients from LF, HBV-carriers and healthy controls, the area under the receiver operating characteristic (ROC) curve is 0.871, with a sensitivity of 0.818 and specificity of 0.819. The survival analysis revealed that higher fuc-fetuin A level was significantly associated with worse recurrence-free survival in HCC patients (p=0.018).

Conclusions: The results indicated that the serum fuc-fetuin A might serve as a potential glycan biomarker for distinguishing LC and HCC from LF, HBV-carriers and healthy controls. Furthermore, the preoperative fuc-fetuin A level could be a useful prognostic biomarker for HCC patients.

Keywords: fetuin A; fucosylation; glycan biomarker; liver disease
Corresponding author: Chunfang Gao, Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Phone: +86 21 81875130, Fax: +86 21 65562400, E-mail:
aLi Li and Xing Gu contributed equally to this work.

Acknowledgments

This work was supported by China National Key Projects for Infectious Disease (No. 2012ZX10002-016) and National Natural Science Foundation of China (No. 81271925 and 81301516).

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Mathew S, Ali A, Abdel-Hafiz H, Fatima K, Suhail M, Archunan G, et al. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infect Genet Evol 2014;26C:327–39.10.1016/j.meegid.2014.06.014Suche in Google Scholar PubMed

2. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445–54.10.1148/radiology.219.2.r01ma40445Suche in Google Scholar PubMed

3. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46:1426–35.10.1002/hep.21855Suche in Google Scholar PubMed

4. Zhang XF, Lai EC, Kang XY, Qian HH, Zhou YM, Shi LH, et al. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 2011;18:2218–23.10.1245/s10434-011-1613-7Suche in Google Scholar PubMed

5. Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009;8:595–602.10.1021/pr800752cSuche in Google Scholar PubMed PubMed Central

6. Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010;56:823–31.10.1373/clinchem.2009.139295Suche in Google Scholar PubMed

7. Sun C, Chen P, Chen Q, Sun L, Kang X, Qin X, et al. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochim Biophys Sin (Shanghai) 2012;44:765–73.10.1093/abbs/gms055Suche in Google Scholar PubMed

8. Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y, et al. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med 2015;53:95–102.10.1515/cclm-2014-0427Suche in Google Scholar PubMed

9. Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, Makridakis M, Vougas K, Fountoulakis M, et al. Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications. Mol Cell Proteomics 2008;7:591–9.10.1074/mcp.M700422-MCP200Suche in Google Scholar PubMed

10. Sakwe AM, Koumangoye R, Goodwin SJ, Ochieng J. Fetuin-A ({alpha}2HS-glycoprotein) is a major serum adhesive protein that mediates growth signaling in breast tumor cells. J Biol Chem 2010;285:41827–35.10.1074/jbc.M110.128926Suche in Google Scholar PubMed PubMed Central

11. Kalabay L, Jakab L, Prohaszka Z, Fust G, Benko Z, Telegdy L, et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 2002;14:389–94.10.1097/00042737-200204000-00009Suche in Google Scholar PubMed

12. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007;4:437–44.10.1038/nmeth1035Suche in Google Scholar PubMed

13. Tsai TH, Wang M, Di Poto C, Hu Y, Zhou S, Zhao Y, et al. LC-MS profiling of N-glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J Proteome Res 2014;13:4859–68.10.1021/pr500460kSuche in Google Scholar PubMed PubMed Central

14. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005;102:779–84.10.1073/pnas.0408928102Suche in Google Scholar PubMed PubMed Central

15. Tanabe K, Deguchi A, Higashi M, Usuki H, Suzuki Y, Uchimura Y, et al. Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients. Biochem Biophys Res Commun 2008;374:219–25.10.1016/j.bbrc.2008.06.124Suche in Google Scholar PubMed

16. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006;5:308–15.10.1021/pr050328xSuche in Google Scholar PubMed

17. Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer 2010;127:148–59.10.1002/ijc.25030Suche in Google Scholar PubMed

18. Ji J, Gu X, Fang M, Zhao Y, Yi C, Wang A, et al. Expression of alpha 1,6-fucosyltransferase 8 in hepatitis B virus-related hepatocellular carcinoma influences tumour progression. Dig Liver Dis 2013;45:414–21.10.1016/j.dld.2012.12.007Suche in Google Scholar PubMed

19. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T, et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 2003;63:6282–9.Suche in Google Scholar

20. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797–806.10.1074/jbc.M605697200Suche in Google Scholar PubMed

21. Nakagawa T, Moriwaki K, Terao N, Miyamoto Y, Kamada Y, Miyoshi E. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J Proteome Res 2012;11:2798–806.10.1021/pr201154kSuche in Google Scholar PubMed

22. Nakagawa T, Takeishi S, Kameyama A, Yagi H, Yoshioka T, Moriwaki K, et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J Proteome Res 2010;9:4888–96.10.1021/pr100414rSuche in Google Scholar PubMed

23. Cao Y, Chang H, Li L, Cheng RC, Fan XN. Alteration of adhesion molecule expression and cellular polarity in hepatocellular carcinoma. Histopathology 2007;51:528–38.10.1111/j.1365-2559.2007.02820.xSuche in Google Scholar PubMed

24. Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, et al. Wnt signaling in liver fibrosis: progress, challenges and potential directions. Biochimie 2013;95:2326–35.10.1016/j.biochi.2013.09.003Suche in Google Scholar PubMed

25. Desmet VJ. The amazing universe of hepatic microstructure. Hepatology 2009;50:333–44.10.1002/hep.23152Suche in Google Scholar PubMed

26. Musch A. The unique polarity phenotype of hepatocytes. Exp Cell Res 2014;328:276–83.10.1016/j.yexcr.2014.06.006Suche in Google Scholar PubMed PubMed Central

27. Zwenger A, Rabassa M, Demichelis S, Grossman G, Segal-Eiras A, Croce MV. High expression of sLex associated with poor survival in Argentinian colorectal cancer patients. Int J Biol Markers 2014;29:e30–9.10.5301/jbm.5000060Suche in Google Scholar PubMed

28. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755–61.10.1074/jbc.271.22.12755Suche in Google Scholar PubMed

29. Venkatachalam MA, Weinberg JM. New wrinkles in old receptors: core fucosylation is yet another target to inhibit TGF-beta signaling. Kidney Int 2013;84:11–4.10.1038/ki.2013.95Suche in Google Scholar PubMed

30. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006;281:2572–7.10.1074/jbc.M510893200Suche in Google Scholar PubMed

31. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA 2005;102: 15791–6.10.1073/pnas.0507375102Suche in Google Scholar PubMed PubMed Central

32. Pompach P, Brnakova Z, Sanda M, Wu J, Edwards N, Goldman R. Site specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics 2013;12: 1281–93.10.1074/mcp.M112.023259Suche in Google Scholar PubMed PubMed Central

Supplemental Material

The online version of this article (DOI: 10.1515/cclm-2015-0307) offers supplementary material, available to authorized users.

Received: 2015-2-3
Accepted: 2015-4-17
Published Online: 2015-6-2
Published in Print: 2016-4-1

©2016 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Macroprolactin: searching for a needle in a haystack?
  4. Review
  5. Laboratory medicine in the new healthcare environment
  6. Opinion Paper
  7. Developing GRADE outcome-based recommendations about diagnostic tests: a key role in laboratory medicine policies
  8. EFLM Survey
  9. Accreditation process in European countries – an EFLM survey
  10. Genetics and Molecular Diagnostics
  11. HB Puerta del Sol [HBA1:c.148A>C], HB Valdecilla [HBA2:c.3G>T], HB Gran Vía [HBA2:c.98T>G], HB Macarena [HBA2:c.358C>T] and HB El Retiro [HBA2:c.364_366dupGTG]: description of five new hemoglobinopathies
  12. General Clinical Chemistry and Laboratory Medicine
  13. A candidate reference method using ICP-MS for sweat chloride quantification
  14. Quantification of hemoglobin A1c by off-line HPLC separation and liquid chromatography-tandem mass spectrometry: a modification of the IFCC reference measurement procedure
  15. Comparison between B·R·A·H·M·S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods – a prospective multinational trial
  16. Evaluation of a hand-held blood gas analyzer for rapid determination of blood gases, electrolytes and metabolites in intensive care setting
  17. Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms
  18. A possible cause of the variable detectability of macroprolactin by different immunoassay systems
  19. A multicenter comparison of whole blood vitamin B6 assays
  20. Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays
  21. Development and validation of a 2nd tier test for identification of purine nucleoside phosphorylase deficiency patients during expanded newborn screening by liquid chromatography-tandem mass spectrometry
  22. A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers
  23. Reference Values and Biological Variations
  24. Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children
  25. Development of reference intervals for serum alkaline phosphatase among adults in Southern China traced to the new IFCC reference measurement procedure
  26. Birth season predicts the values of red blood cell distribution width (RDW) in adulthood
  27. Cardiovascular Diseases
  28. Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?
  29. A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of β1-adrenergic receptor autoantibodies in human heart disease
  30. Infectious Diseases
  31. The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases
  32. Letters to the Editor
  33. Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic anemia
  34. Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic anemia: a reply
  35. STORE (Sample Tracking: Organization, Refrigeration and Expansion): a project in a clinical laboratory perspective
  36. Control materials for immunochromatographic strip used for α-thalassemia screening
  37. Comparison of a 10- vs. 15-min centrifugation time for chemical and immunochemical assays and impact on turnaround time in a hospital laboratory
  38. Pre-analytical phase in cryoglobulin (CRG) detection: an alternative method for sample transport
  39. The efficacy of an internet-based e-learning system using the CellaVision Competency Software for continuing professional development
  40. Clinical examinations after the Fukushima disaster: a case report of Soma General Hospital
  41. Non-fasting plasma glucose concentration in blood donors
  42. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study
  43. UBE3A, c.1347_1348delGA: a mutation in question
https://doi.org/10.1515/cclm-2015-0307
Schlagwörter für diesen Artikel
fetuin A; fucosylation; glycan biomarker; liver disease

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Macroprolactin: searching for a needle in a haystack?
  4. Review
  5. Laboratory medicine in the new healthcare environment
  6. Opinion Paper
  7. Developing GRADE outcome-based recommendations about diagnostic tests: a key role in laboratory medicine policies
  8. EFLM Survey
  9. Accreditation process in European countries – an EFLM survey
  10. Genetics and Molecular Diagnostics
  11. HB Puerta del Sol [HBA1:c.148A>C], HB Valdecilla [HBA2:c.3G>T], HB Gran Vía [HBA2:c.98T>G], HB Macarena [HBA2:c.358C>T] and HB El Retiro [HBA2:c.364_366dupGTG]: description of five new hemoglobinopathies
  12. General Clinical Chemistry and Laboratory Medicine
  13. A candidate reference method using ICP-MS for sweat chloride quantification
  14. Quantification of hemoglobin A1c by off-line HPLC separation and liquid chromatography-tandem mass spectrometry: a modification of the IFCC reference measurement procedure
  15. Comparison between B·R·A·H·M·S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods – a prospective multinational trial
  16. Evaluation of a hand-held blood gas analyzer for rapid determination of blood gases, electrolytes and metabolites in intensive care setting
  17. Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms
  18. A possible cause of the variable detectability of macroprolactin by different immunoassay systems
  19. A multicenter comparison of whole blood vitamin B6 assays
  20. Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays
  21. Development and validation of a 2nd tier test for identification of purine nucleoside phosphorylase deficiency patients during expanded newborn screening by liquid chromatography-tandem mass spectrometry
  22. A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers
  23. Reference Values and Biological Variations
  24. Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children
  25. Development of reference intervals for serum alkaline phosphatase among adults in Southern China traced to the new IFCC reference measurement procedure
  26. Birth season predicts the values of red blood cell distribution width (RDW) in adulthood
  27. Cardiovascular Diseases
  28. Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?
  29. A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of β1-adrenergic receptor autoantibodies in human heart disease
  30. Infectious Diseases
  31. The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases
  32. Letters to the Editor
  33. Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic anemia
  34. Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic anemia: a reply
  35. STORE (Sample Tracking: Organization, Refrigeration and Expansion): a project in a clinical laboratory perspective
  36. Control materials for immunochromatographic strip used for α-thalassemia screening
  37. Comparison of a 10- vs. 15-min centrifugation time for chemical and immunochemical assays and impact on turnaround time in a hospital laboratory
  38. Pre-analytical phase in cryoglobulin (CRG) detection: an alternative method for sample transport
  39. The efficacy of an internet-based e-learning system using the CellaVision Competency Software for continuing professional development
  40. Clinical examinations after the Fukushima disaster: a case report of Soma General Hospital
  41. Non-fasting plasma glucose concentration in blood donors
  42. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study
  43. UBE3A, c.1347_1348delGA: a mutation in question
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 9.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2015-0307/pdf
Button zum nach oben scrollen